Drug Profile
ARCT 021
Alternative Names: ARCT 021; Coronavirus Vaccine - Arcturus TherapeuticsLatest Information Update: 24 Jan 2023
Price :
$50
*
At a glance
- Originator Arcturus Therapeutics
- Class COVID-19 vaccines; RNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - COVID 2019 infections
Highest Development Phases
- Discontinued COVID 2019 infections
Most Recent Events
- 24 Jan 2023 Discontinued - Phase-II for COVID-2019 infections (In the elderly, Prevention, In adults) in Singapore (IM)
- 24 Jan 2023 Discontinued - Phase-II for COVID-2019 infections (In the elderly, Prevention, In adults) in USA (IM)
- 08 Jul 2022 Arcturus Therapeutics terminates its phase IIa trial in COVID-2019 infections (Prevention, In adults, In the elderly) in Singapore and USA due to business reasons (IM) (NCT04728347)